NCT04739358View on ClinicalTrials.gov

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

June 23, 2023

Study Completion Date

June 23, 2023

Conditions
Advanced Non-Small Cell Lung Cancer With MET Mutations
Interventions
DRUG

Tepotinib

Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.

Trial Locations (5)

15232

UPMC Hillman Cancer Center, Pittsburgh

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

80045

University of Colorado Cancer Center, Aurora

95817

UC Davis Comprehensive Cancer Center, Sacramento

98195

University of Washington, Seattle

Sponsors

Lead Sponsor

Criterium, Inc.
All Listed Sponsors
collaborator

EMD Serono Research & Development Institute, Inc.

INDUSTRY

lead

Criterium, Inc.

INDUSTRY

NCT04739358 - CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | Biotech Hunter | Biotech Hunter